IVXO
Asset Logo

Invion Limited

🇦🇺 ASX

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

-18.04%
Annual Growth

3 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Invion Limited - Option Expiring 17-Jun-2023

📈 Performance

Price History

-50.00%

1M

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

0%
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.00

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in IVXO

0

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in IVXO

N/A
IVXO investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

🙋 Legal gender of investors

Female

Male

Pearlers who invest in IVXO also invest in...

Want more shares? Try these...

Invictus Energy Ltd

IVZ

Invictus Energy Ltd. Engages in the exploration and appraisal of Cabora Bassa Project. The company is headquartered in Perth, Western Australia. The company went IPO on 2012-01-19. The firm is focused on energy resources in sub-Saharan Africa. Its asset portfolio consists of approximately 360,000 hectares within the Cabora Bassa Basin in Zimbabwe. The Company’s principal asset is SG 4571. SG 4571 covers approximately 250,000 acres located in the prospective portion of the Cabora Bassa Basin in northern Zimbabwe. SG 4571 and EPOs 1848/49 contain the Mukuyu and multiple Basin Margin prospects. The firm has offices in Harare, Zimbabwe. The Company’s subsidiaries include HIS Texas LLC, Invictus Energy Resources Pty Limited, Invictus Energy Mauritius Limited, Invictus Energy Resources Zimbabwe (Pvt) Ltd and Geo Associates (Pvt) Ltd.

📊 Share price

$0.14 AUD
Find Out More

📊 Share price

$0.00 AUD

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

📊 Share price

$43.11 AUD

NULL US

NULL EX AUSTRALIA

NULL BETA

Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for a variety of cancers, atherosclerosis and infectious diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The firm is engaged in the clinical development of a PhotoDynamic Therapy (PDT) for cancer. Its photosensitizer (the agent used in PDT) is called IVX-PDT and is based on Photosoft Technology. Its PDT is an alternative to surgery, and in contrast to radiotherapy and chemotherapy, which are immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumor by leukocytes. The company produces topical and intravenous products suitable for use in skin cancer and in solid tumors, such as those present in ovarian, prostate and lung cancer. The company is developing a topical formulation of its photosensitizing agent, IVX-PDT, to treat superficial Basal Cell Carcinoma (sBCC), Actinic Keratosis (AK) and Squamous Cell Cancer (SCC).

📊 Share price

$0.01 AUD
Compare
Add to watchlist